TITLE:
Effects of Statin Therapy on Endothelial Function in Asymptomatic Metabolic Syndrome
AUTHORS:
Boochi Babu Mannuva, Rajasekhar Durgaprasad, Vanajakshamma Velam, Vinod Kumar Mustyala, Latheef Kasala, Ashok Thakkar
KEYWORDS:
Metabolic Syndrome; Endothelial Dysfunction; Flow-Mediated Dilation; Brachial Artery; Statin
JOURNAL NAME:
International Journal of Clinical Medicine,
Vol.5 No.4,
February
15,
2014
ABSTRACT: Context: Endothelial dysfunction is an early
predictor of adverse cardiovascular events. The present study evaluated
asymptomatic metabolic syndrome (MS) patients with brachial artery endothelial
dysfunction to determine
whether a reversal of endothelial dysfunction occurs with statin treatment.
Aim: To evaluate the short term effects of statins on endothelial function in
asymptomatic metabolic syndrome patients. Methodology: This was a prospective,
single centre, case-control study. We evaluated 50 recently diagnosed newly
detected asymptomatic MS
patients who underwent an assessment of endothelial function by brachial artery
flow-mediated dilation (FMD)
before and after treatment with 40 mg atorvastatin for one week. Results: A
total of 50 MS patients, including 36 (62%) females and 14 (38%) males, were
included in the study. The mean age of the patients was 49.70 ± 8.84 y. We
identified a significant difference between cases and age- and sex-matched
controls regarding baseline brachial artery FMD% (6.73 ± 2.55 vs. 11.03 ± 1.85, respectively; p lations were
detected between FMD% and HDL-cholesterol (r = -0.34, p = 0.01), fasting
blood sugar (r = -0.40, p = 0.004), and systolic blood pressure (r =
-0.34, p = 0.015). Multiple linear regression analysis indicated that
HDL-cholesterol was an independently associated factor for FMD. MS patients treated with 40 mg atorvastatin for one week
showed a significant improvement in brachial artery FMD% (6.73 ± 2.55
before treatment vs. 10.19 ± 3.01 after treatment, p dothelial
function in MS patients.